Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BDRX 
Biodexa Pharmaceticals (BDRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/12/2025: BDRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $178.33
1 Year Target Price $178.33
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -20.75% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.49M USD | Price to earnings Ratio - | 1Y Target Price 178.33 |
Price to earnings Ratio - | 1Y Target Price 178.33 | ||
Volume (30-day avg) 1 | Beta 0.95 | 52 Weeks Range 5.00 - 74.70 | Updated Date 11/12/2025 |
52 Weeks Range 5.00 - 74.70 | Updated Date 11/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -26.34 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -39.04% | Return on Equity (TTM) -61.77% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1161941 | Price to Sales(TTM) 0.58 |
Enterprise Value -1161941 | Price to Sales(TTM) 0.58 | ||
Enterprise Value to Revenue 4.7 | Enterprise Value to EBITDA 0.03 | Shares Outstanding 619523 | Shares Floating 60827246232 |
Shares Outstanding 619523 | Shares Floating 60827246232 | ||
Percent Insiders 0.95 | Percent Institutions 6.1 |
Upturn AI SWOT
Biodexa Pharmaceticals
Company Overview
History and Background
Biodexa Pharmaceuticals PLC (formerly known as Nucana Biomarkers) is a clinical-stage biopharmaceutical company focused on developing novel therapies for unmet medical needs. Founded with a focus on improving cancer treatments, it has evolved to address various conditions.
Core Business Areas
- Lead Program - MTX110: Development and commercialization of MTX110, a proprietary formulation of methotrexate, for the treatment of recurrent high-grade glioma (HGG) and other cancers affecting the central nervous system.
- Other Pipeline Programs: Focus on developing additional therapies and formulations for various diseases with significant unmet medical needs.
Leadership and Structure
The leadership team comprises individuals with experience in pharmaceuticals, biotechnology, and finance. The organizational structure consists of research and development, clinical operations, and commercialization teams.
Top Products and Market Share
Key Offerings
- MTX110: MTX110 is the lead product candidate, a proprietary formulation of methotrexate designed for direct delivery to the brain via convection-enhanced delivery (CED). Currently in clinical development for recurrent high-grade glioma (HGG). Market share data not yet applicable as the product is not commercialized. Competitors include standard chemotherapy regimens and other experimental therapies for HGG.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Focus areas include oncology, rare diseases, and neurological disorders.
Positioning
Biodexa Pharmaceuticals is positioned as a company focused on developing targeted therapies for unmet medical needs, particularly in oncology. Its competitive advantage lies in its proprietary drug delivery technology and its focus on difficult-to-treat cancers.
Total Addressable Market (TAM)
The TAM for recurrent high-grade glioma is estimated to be significant, with a growing incidence rate. Biodexa's MTX110 is positioned to capture a portion of this market if approved, targeting a niche of patients with limited treatment options.
Upturn SWOT Analysis
Strengths
- Proprietary drug delivery technology (CED)
- Focus on unmet medical needs
- Lead product candidate in clinical development
- Experienced leadership team
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- No currently marketed products
- High risk of clinical trial failure
Opportunities
- Potential for regulatory approval of MTX110
- Expansion of pipeline through acquisitions or collaborations
- Application of drug delivery technology to other diseases
- Partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Competition from other therapies
- Regulatory hurdles
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- BMY
- MRK
- LLY
Competitive Landscape
Biodexa Pharmaceuticals competes with larger pharmaceutical companies and biotechnology firms in the oncology space. Its competitive advantage lies in its targeted therapies and drug delivery technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by progress in clinical development and expansion of the pipeline.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approval of MTX110 and other pipeline candidates.
Recent Initiatives: Recent initiatives include advancing the clinical development of MTX110, exploring potential collaborations, and securing additional funding.
Summary
Biodexa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies for unmet medical needs. The company's lead product candidate, MTX110, is in clinical development for recurrent high-grade glioma. Successful clinical trial outcomes and regulatory approval are critical for the company's future growth. However, limited financial resources and clinical trial risks remain challenges.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Databases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biodexa Pharmaceticals
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-12-07 | CEO, CFO, Company Secretary & Director Mr. Stephen Anthony Stamp | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.biodexapharma.com |
Full time employees 13 | Website https://www.biodexapharma.com | ||
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.